Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

JQ1 (+/-)

Inh 1268524-69-1 (6R,S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester
Catalog No. ABIN7233265
  • Application
    Inhibition (Inh)
    Purpose
    Bromodomain inhibitor
    Characteristics
    JQ1 is a potent BET bromodomain inhibitor. IC50 = 17.7, 32.6, 76.9 and 12942 nM respectively for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP respectively. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models establishing proof-of-concept for targeting protein-protein interactions of epigenetic readers.
    Purity
    >98 %
    Chemical Name
    (6R,S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester
    Formula
    C23H25ClN4O2S
    Solubility
    Soluble in DMSO (up to 9 mg/ml) or in Ethanol (up to 9 mg/ml) with warming.
  • Restrictions
    For Research Use only
  • Format
    Powder
    Precaution of Use
    GHS – Classification
    Pharmacologically active compound that has not been fully tested
    May be harmful if swallowed, inhaled or absorbed through skin
    Exposure may cause irritation to skin, eyes and upper respiratory tract
    Specific target organ toxicity - unknown
    Storage
    RT
  • Background
    Epigenetics,Proliferation,Bromodomain,Cancer,Posttranslational modification,Chromatin
    Molecular Weight
    457.00
    CAS-No
    1268524-69-1
You are here:
Support